BOND BONE

{0}------------------------------------------------ K101014 Implants Technologies Ltd. ### 510(k) Summary: Bond Bone™ Company Name: MIS Implants Technologies Ltd. P.O.Box 7 Bar Lev Industrial Park 20156, ISRAEL Telephone: +972-4-901-6800 Fax: +972-4-991-8623 Establishment Registration Number: 3004203816 - Contact Name: Iman Khorshid VP Quality & Regulatory Affairs Telephone: +972-4-901-6800 Fax: +972-4-991-8623 E-mail: iman@mis-implants.com US Agent: Motti Weisman - VP Marketing MIS Implants Technologies Inc. 14-25 Plaza Rd. Suite S-3-5 Fair Lawn New Jersey; 07410 Phone: (201) 797-9144 (201) 797-9145 Fax: E-mail: service@misimplants.com Date prepared: July 30, 2010 Trade Name: Bond Bone™ Classification name: Bone Grafting Materials Common/usual name: Bone Grafting Materials, Synthetic Product Code: LYC Regulation No.: 872.3930 Class: II Classification Panel: Dental Products Panel 510 (k) Bond Bone™ Section E - Page 1 of 12 {1}------------------------------------------------ # Implants Technologies Ltd. #### Predicate Device: Bond Bone™ from Augma Biomaterials Ltd., Usishkin 8, Netanya 42273, Israel cleared under 510(k) No. K083858. #### Description of the device: Bond Bone™ is a synthetic osteoconductive, bioresorbable bone grafting material composed of biphasic calcium sulfate in granulated powder form, intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region. When mixed with saline, Bond Bone forms a paste and hardens via a cementitious reaction. The product is provided sterile and for single patient use. #### Indications for Use: Bond Bone™ is indicated for use in the following ways: by itself in bone regenerative techniques, mixed with other suitable bone filling agents to prevent particle migration in an osseous defect, and to provide a resorbable barrier over other bone graft material. #### Substantial Equivalence: Bond Bone™ has the same intended use as Bond Bone™ from Augma Biomaterials Ltd., Usishkin 8, Netanya 42273, Israel cleared under 510(k) No. K083858, and has same performance characteristics. Bond Bone™ is therefore substantially equivalent to the predicate device. #### Performance testing: Bond Bone™ has been tested for a number of chemical and physical characteristics: chemical composition, phase composition, trace of impurities, density and porosity, particle size, morphology, setting time and reaction temperature, compressive strength and elastic modulus, pH analysis and dissolution rate. All these characteristics are equivalent to those of the predicate device. 510 (k) Bond Bone™ Section E - Page 2 of 13 {2}------------------------------------------------ ## Implants Technologies Ltd. #### Conclusion: The evaluation of Bond Bone™ does not raise any additional concerns regarding safety and effectiveness and may therefore be considered substantially equivalent to its predicate device. 510 (k) Bond Bone™ Section E – Page 3 of 13 {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular fashion around the symbol. The text is in all caps and appears to be in a sans-serif font. The overall design is simple and professional. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Ms. Iman Khorshid Vice President Quality & Regulatory Affairs MIS Implants Technologies Limited P.O. Box 7 Bar Lev Industrial Park Israel 20156 OCT 2 1 2010 Re: K101014 Trade/Device Name: Bond Bone™ Regulation Number: 21 CFR 872.3930 Regulation Name: Bone Grafting Material Regulatory Class: II Product Code: LYC Dated: September 7, 2010 Received: September 9, 2010 Dear Ms. Khorshid: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ #### Page 2- Ms. Khorshid Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. ' Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor Y.ou/Industry/default.htm. Sincerely vours. Rh for Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology. General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ Image /page/5/Picture/0 description: The image shows the logo for MIS Implants Technologies Ltd. The logo features the letters "MIS" in a stylized font, with the "I" being taller than the other letters. To the right of the logo is the text "Implants Technologies Ltd." in a smaller font. The text is right-aligned with the "S" in the logo. OCT 2 1 2010 | 510(k) Number (if known): | K101014 | |---------------------------|---------| |---------------------------|---------| | INDICATIONS FOR USE | |---------------------| |---------------------| Bond Bone™ Device Name: Indications for Use: Bond Bone™ is indicated for use in the following ways: by itself in bone regenerative techniques, mixed with other suitable bone filling agents to prevent particle migration in an osseous defect, and to provide a resorbable barrier over other bone graft material. Prescription Use X OR (Part 21 CFR 801 Subpart D) Over the Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE -CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Susan Runser (Division Sign-Off) (Division Sign-Off) Division of Anesthesiology, General Hospital Division of Anesthesiology, General Devices Division Control, Dental Devices 510(k) Number: 510 (k) UNO Narrow Implant Section D- Page 1 of 1